2025年最新のFast2test RAPS RAC-US問題集と試験テストエンジン
RAPS RAC-US問題集にはリアル試験問題解答
RAC-US認定は、専門家の専門知識とキャリアアップの機会を向上させたい規制関連の専門家にとって、貴重な資格です。試験は厳格で難解であり、規制関連に関連する幅広いトピックを扱います。認定には、求人の機会の向上、収益の可能性の向上、規制関連の専門家とリソースへのアクセスが含まれます。キャリアアップを目指す規制関連の専門家であれば、RAC-US認定が適切な選択肢になるかもしれません。
RAPS RAC-US認定試験は、医療産業の規制関連全般をカバーする包括的な試験です。この試験は、規制戦略、製品開発、臨床試験、規制申請、品質システム、そして市場後の活動などのトピックを扱います。この試験は、米国の規制および規制要件に関する候補者の知識、およびその知識を実践的な場面で適用する能力をテストするよう設計されています。
RAPS RAC-US試験は、120の多肢選択問題から構成されるコンピュータベースのテストです。この試験は、米国内にあるPearson VUEテストセンターで実施されます。試験はタイム制であり、受験者は4時間以内に試験を完了する必要があります。
質問 # 45
You discover that your company's top selling product in the last two years has been used off-label.
The off-label use is estimated to be about 70%, and it has been consistent since the product was first released to the market. Which of the following is MOST appropriate?
- A. No action is required since it is an off-label use.
- B. Discuss with regulatory authorities to investigate how to have the off-label indication approved.
- C. File a report to regulatory authorities and advise the marketing department to prevent future off-label use.
- D. Advise the senior management to send a "Dear Dr." letter.
正解：B
質問 # 46
Which of the following changes to a drug product is MOST likely to be implemented without prior regulatory authority approval?
- A. Deleting an ingredient of the drug product
- B. Introducing a new analytical method
- C. Deleting a drug substance
- D. Strengthening a precaution to the product labeling
正解：D
質問 # 47
Which of the following is the MOST desirable timing and approach for a regulatory affairs professional who wants to provide feedback on proposed new regulations?
- A. After the enactment of the regulation, through the industry representative
- B. Before the enactment of the regulation, through the industry representative
- C. After the enactment of the regulation, through a product-specific meeting
- D. Before the enactment of the regulation, through formal comments gathering process
正解：D
質問 # 48
At a recent scientific meeting, Company Y had two booths:
* At one booth, Company Y provided brochures on a completed Phase II study.
* In an adjacent booth, Company Y's sales professionals were promoting one of Company
Y's marketed products.
A regulatory affairs-professional at Company X sends a letter to a counterpart at Company
Y requesting that Company Y stop this practice in the future and demanding a formal response to the letter. How should the regulatory affairs professional at Company Y BEST respond?
- A. Inform the legal department of the letter and discuss how to respond.
- B. Acknowledge receipt of the letter in a written response but do nothing further.
- C. Inform Company X that it has no right to send such a letter and do nothing further.
- D. Inform the local regulatory authority of the letter and discuss how to respond.
正解：A
質問 # 49
In the process of obtaining a product approval, a regulatory affairs professional discovers that the product does not meet one of the specific technical requirements of the regulation.
However, competitors with substantially similar products have claimed compliance with the requirement and received approval. Which action should the regulatory affairs professional take FIRST?
- A. Notify senior management that the product cannot be registered.
- B. Inform the internal departments to redesign the product to comply with this requirement.
- C. Inform the regulatory authority that such a requirement is not applicable to the product.
- D. Discuss with the regulatory apriority and attempt to reach an acceptable solution.
正解：D
質問 # 50
The manufacturer of an API was changed from Company X to Company Y during the late stage of a new drug development. Despite differences in the manufacturing processes of the companies, both APIs meet the current specifications. Which is the MOST appropriate information to include in the final submission documents?
- A. The process information and analytical result of Company X API
- B. The process information and analytical result of Company Y API
- C. The process information and the comparative analytical result of APIs from both companies
- D. Information deemed appropriate by the regulatory authority
正解：C
質問 # 51
During several monitoring visits, a clinical trial monitor identifies serious and repeated noncompliance on the part of the PI. What action should the sponsor take?
- A. Increase the frequency of monitoring visits.
- B. Terminate the PI and inform the regulatory authorities.
- C. Send a letter of complaint to the Ethics Committee that approved the site.
- D. Inform the institution that granted a medical license to the Pi.
正解：B
質問 # 52
The API used for an approved drug product conforms to international monograph specifications and local pharmacopeia; however, the international monograph specifications of the API will be changing soon. Which is the most appropriate action for the regulatory affairs professional to take FIRST?
- A. Prepare the international monograph change submission first and then prepare the local change when required.
- B. Transfer the notice of the upcoming international monograph change to QA for further processing.
- C. Analyze the impact of the international monograph change on the local pharmacopeia.
- D. Confirm that the international monograph change is not related to local pharmacopeia.
正解：B
質問 # 53
A materials supplier informs a company that it intends to stop supplying a material critical to the manufacture of the company's products. What action should the company take FIRST?
- A. Qualify another supplier and execute a supplier agreement.
- B. Reformulate the products with a replacement material.
- C. Complete a gap analysis to identify options.
- D. Review the company's existing Quality Management System
正解：A
質問 # 54
Who has the PRIMARY responsibility for recall of products with quality defects?
- A. Regulatory authority
- B. Manufacturer
- C. Consumer
- D. Distributor
正解：B
質問 # 55
The regulatory authority in Country X issued a request for a mandatory product recall in
Country X due to serious injuries to patients. This product also is distributed in Country Y.
What should the regulatory affairs professional of the product's manufacturer FIRST do in
Country Y?
- A. Prepare the legal team in Country Y for possible litigations.
- B. Initiate a mandatory recall of the product in Country Y.
- C. Review alt distribution records and complaints reported in Country Y.
- D. Draft a formal letter to customers in Country Y about this recall.
正解：C
質問 # 56
Which analysis method is MOST appropriate to prioritize risk and monitor the effectiveness of risk control activities for a medical device?
- A. Fault tree analysis
- B. Failure modes, effects, and criticality analysis
- C. Fishbone analysis
- D. Quality by design analysis
正解：B
質問 # 57
During the review of a design dossier, the reviewer asks why the company has only carried out a top-down risk approach. The reviewer is referring to which of the following?
- A. Fault tree analysis
- B. Hazard and operability study
- C. Failure mode and effect analysis
- D. ISO 14971 risk analysis
正解：D
質問 # 58
Under which of the following circumstances would a regulatory authority require a more detailed premarket submission, a more rigorous audit, and/or the provision of more performance evaluation data than would normally apply to an IVD device of that risk class?
- A. The manufacturer's experience level with the type of IVD medical device is limited.
- B. Internationally recognized standards are available to cover the main aspects of the device and have been used by the manufacturer.
- C. The device incorporates well-established technology that is already present in the market.
- D. The device is an updated version of a compliant device from the same manufacturer and contains no substantive change.
正解：A
質問 # 59
Which of the following criteria is MOST appropriate to define the animal species needed for the pre-clinical toxicity testing of a biotechnology product?
- A. Proposed product route and frequency of administration
- B. Proposed dose and volume of administration
- C. Biological activity with species and/or tissue specificity
- D. Immunochemical and functional tests
正解：C
質問 # 60
A manufacturer is involved in a recall event process for a plasma-derived product. From which stage should the manufacturer be able to trace back the product?
- A. Plasma fractionation
- B. Plasma pooling
- C. Product distribution
- D. Individual plasma donation
正解：C
質問 # 61
A request was received from a regulatory authority asking the company to conduct product testing in compliance with a newly issued regulation.
What should be done. What action should the company take FIRST?
- A. Consult with colleagues about the request.
- B. Send a letter back to the regulatory authority indicating why the regulation does not apply to the product.
- C. Initiate testing immediately to ensure compliance.
- D. Contact the regulatory authority that issued this request and discuss the requirement.
正解：D
質問 # 62
A superiority advertising claim for a product versus its competitor's product can only be made under which of the following circumstances?
- A. Results of adequate, well-controlled comparative clinical trial show the product is superior.
- B. In vitro studies show the product to be superior.
- C. Results of a three-year, post-market patient survey indicate the product is superior.
- D. Government survey data indicate the product is superior.
正解：A
質問 # 63
......
2025年最新のFast2test RAC-USのPDFで最近更新された問題です：https://jp.fast2test.com/RAC-US-premium-file.html
RAC-US試験には保証が付きます。更新されたのは100問があります：https://drive.google.com/open?id=1cN151_TD65lsRjaWZE4vIPRUfPpui5Po